N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2

Inventors: Christine Hiu-Tung Chen (Waltham, MA); Zhuoliang Chen (Belmont, MA); Michael Dore (Wilmington, MA); Jorge Garcia Fortanet (Wilmington, MA); John William Giraldes (Windsor Mill, MD); Rajesh Karki (Quincy, MA); Mitsunori Kato (Cambridge, MA); Matthew J. LaMarche (Reading, MA); Lawrence Blas Perez (Silver Spring, MD); Martin Sendzik (Belmont, MA); Troy Douglas Smith (Nashua, NH); Bakary-Barry Toure (Weston, MA); Sarah Williams (Livermore, CA)

Assignee: NOVARTIS AG

C07D498/10 C07D241/18 C07D241/20 C07D401/04 C07D401/14 C07D403/04 C07D471/10 C07D491/107 C07D495/10 C07B2200/07

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,968,235
App. No.: 16/418,978
Granted: Apr 6, 2021
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to compounds of formula I: in which p, q, Y 1 , Y 2 , R 1 , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 7 and R 8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Claims (3)

1. A compound, or a pharmaceutically acceptable salt thereof, selected from:

2. A compound which is

3. A compound which is

Assignments (6)